These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38706223)

  • 1. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
    Cárdenas-Soto K; Dominguez XH; Cortes G; Tsai F; Saniger MDM; Guraieb-Chahin P; Torres-Ocatvo B; Gibbons C; Kelly JW; Freeman R; González-Duarte A
    J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
    Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M
    Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
    J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.
    Leonardi L; Adam C; Beaudonnet G; Beauvais D; Cauquil C; Not A; Morassi O; Benmalek A; Trassard O; Echaniz-Laguna A; Adams D; Labeyrie C
    Eur J Neurol; 2022 May; 29(5):1477-1487. PubMed ID: 35100482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
    J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
    Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
    Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
    Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Amass L; Li H; Gundapaneni BK; Schwartz JH; Keohane DJ
    Orphanet J Rare Dis; 2018 Dec; 13(1):225. PubMed ID: 30558645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
    Patil MB; Ghode P; Joshi P
    Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
    Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy.
    Masuda T; Ueda M; Suenaga G; Misumi Y; Tasaki M; Izaki A; Yanagisawa Y; Inoue Y; Motokawa H; Matsumoto S; Mizukami M; Arimura A; Deguchi T; Nishio Y; Yamashita T; Inomata Y; Obayashi K; Ando Y
    Neurology; 2017 Jun; 88(23):2192-2197. PubMed ID: 28490654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy.
    Sanso MAR; Rodriguez AR; Vicente LM; Sevilla T; Garro CB; Martín JF; Vicente AA; de la Prida MM; Dávila LG; Vázquez LG; Valle FM; Pons CC; Bau AF; Barroso EC; López IL; González-Moreno J
    Med Clin (Barc); 2024 May; 162(9):e27-e32. PubMed ID: 38556397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
    Galosi E; Costanzo R; Forcina F; Morino S; Antonini G; Salvetti M; Lauletta A; Luigetti M; Romano A; Primiano G; Guglielmino V; Fionda L; Garibaldi M; Esposito N; Falco P; di Pietro G; Truini A; Leonardi L
    Neurol Sci; 2024 Oct; 45(10):5023-5032. PubMed ID: 38700599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review.
    Cruz MW
    Clin Auton Res; 2019 Sep; 29(Suppl 1):19-24. PubMed ID: 31407119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019).
    Adams D; Cintas P; Solé G; Tard C; Labeyrie C; Echaniz-Laguna A; Cauquil C; Pereon Y; Magy L; Morales RJ; Antoine JC; Lagrange E; Petiot P; Mallaret M; Francou B; Guiochon-Mantel A; Coste A; Demarcq O; Geffroy C; Famelart V; Rudant J; Bartoli M; Donal E; Lairez O; Eicher JC; Kharoubi M; Oghina S; Trochu JN; Inamo J; Habib G; Roubille F; Hagège A; Morio F; Cariou E; Adda J; Slama MS; Charron P; Algalarrondo V; Damy T; Attarian S
    Rev Neurol (Paris); 2024 Sep; 180(7):661-672. PubMed ID: 38643028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.